Head-to-head · Cost-Efficiency Index
Renlo Health vs Maves
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Renlo Health
Someone who wants a flat monthly bill that will not step up, with a refund route if it does not work.
Visit Renlo HealthMaves
Shoppers drawn to aggressive low intro pricing on semaglutide who will confirm the exact charge before checkout.
Visit MavesThe verdict
Renlo Health takes it, leading the Cost-Efficiency Index 78 to 76. A price lock, a named prescriber and a named pharmacy — and a headline that is the actual monthly rate rather than a prepay divided down. Maves still earns a C — Shoppers drawn to aggressive low intro pricing on semaglutide who will confirm the exact charge before checkout.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Renlo Health.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Renlo Health | Maves |
|---|---|---|
| Cost-Efficiency Index | 78/100 | 76/100 |
| Semaglutide / mo | $199/mo, billed monthly at every dose | $89/mo (starting dose, compounded) |
| Tirzepatide / mo | $269/mo, billed monthly at every dose | Not disclosed |
| Semaglutide / yr (modeled) | $2,388 | $1,068 |
| Tirzepatide / yr (modeled) | $3,228 | — |
| Coverage | Not disclosed | All 50 states |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Yes |
| Rank here | #42 | #49 |
Renlo Health
78/100Where the value is
- The headline is the real month-to-month rate — no prepay division and no commitment behind an asterisk
- Names the prescribing physician, Dr. Sean Arora, MD, and the dispensing pharmacy, VialsRX
- Same price at every dose with a price-lock badge, so titrating up never moves the bill
The tradeoffs
- A struck-through $299 sits beside the price with no published basis — Renlo never says what it was, when it applied or to whom
- That strikethrough comes from a stylesheet rule rather than a struck-out element, so a markup-level check would report the page clean
Maves
76/100Where the value is
- LegitScript badge displayed on the site
- Publishes the FDA compounded-medication disclaimer
- Low advertised semaglutide entry price ($89-99/mo range)
The tradeoffs
- The homepage shows two different numbers for the same starting semaglutide tier ($89/month vs $99 first month) with no reconciliation — the real ongoing price cannot be confirmed from the public site
- Tirzepatide is listed as an offering but no price is published anywhere reachable on the site, confirmed by direct search
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.